30 January 2015AmericasJudith Kim and Scott Schaller

After Alice: the two-step rule

Patent-eligible subject matter in the US includes four statutory categories defined in title 35, section 101 (§101) of the US code as “any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof”.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Moderna: BioNTech is claiming work ‘it never did’

12 June 2026 In a strong response to BioNTech, Moderna argues its next-gen vaccine is built on a fundamentally different design from the German biotech’s—setting up a scrap over whether a key patent should have been granted.

Americas

US biotech fires trade secrets suit at Chinese pharma group

10 June 2026 Valuable antibody technology, a former employee, and a dispute over patent rights extending across the US, Europe and Asia at the heart of the latest suit.

Americas

Hikma v Amarin: Six takeaways from the pivotal ruling

9 June 2026 A unanimous SCOTUS ruling is being hailed as a major win for Hikma, and for delivering some welcome clarity. Experts tell Marisa Woutersen how its implications could affect pharma patent strategy across the sector.

More features

Moderna: BioNTech is claiming work ‘it never did’

MoFo bags IP trial duo with 50 years’ combined experience

US biotech fires trade secrets suit at Chinese pharma group

Hikma v Amarin: Six takeaways from the pivotal ruling

Fed Circ rejects Nexus’ appeal in generics row with biopharma firm

Hikma triumphs at SCOTUS in landmark skinny-label ruling

Pfizer strikes $10.5 billion oncology deal with Chinese biotech

Heated LNP litigation puts Moderna and Acuitas in the spotlight

After Alice: the two-step rule

More on this story

Editor's picks

Editor's picks

More features